Using Medicare claims data, they find that between the first quarter of 2019 and the second quarter of 2022, Herceptin’s average sales price fell 21 percent.
Also, "By the end of the second quarter of 2022, the biosimilars’ average sales prices ranged from 28 percent
to 58 percent of the originator’s average sales price in the first quarter of 2019." This finding suggests that biosimilars are effectively making biologic markets more competitive.
Herceptin also lost market share following the introduction of biosimilars.
Visit healthaffairs.org for more on the impact of biosimilars on biologic markets.
Read Health Affairs’ new Forefront series, Private Sector Solutions for Health Equity, featuring health equity experts as they examine private-sector initiatives and responsibility to advance health equity. The series includes articles exploring private-sector efforts to challenge injustices in health care. Topics covered include cardiovascular health, mental health, and maternal health.
Health Affairs is the leading peer-reviewedjournalat the intersection of health, health care, and policy. Published monthly by Project HOPE, the journal is available in print and online. Late-breaking
content is also found through healthaffairs.org, Health Affairs Today, and Health Affairs Sunday Update.
Project HOPE is a global health and humanitarian relief organization that places power in the hands of local health care workers to save lives across the globe. Project HOPE has published Health Affairs since 1981.
